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Generation of tissue-specific cells from MSC
does not require fusion or donor-to-host
mitochondrial/membrane transfer
Evan J. Colletti a, Judith A. Airey b, Wansheng Liu a,1, Paul J. Simmons c,
Esmail D. Zanjani a, Christopher D. Porada a, Graça Almeida-Porada a,*a Department of Animal Biotechnology, University of Nevada at Reno, Reno, NV 89557, USA
b Department of Pharmacology, University of Nevada at Reno, Reno, NV 89557, USA
c The Brown Foundation Institute of Molecular Medicine, University of Texas at Houston, Houston, TX 77030, USAReceived 25 February 2008; received in revised form 27 August 2008; accepted 27 August 2008Abstract Human mesenchymal stem cells (MSC) hold great promise for cellular replacement therapies. Despite their
contributing to phenotypically distinct cells in multiple tissues, controversy remains regarding whether the phenotype switch
results from a true differentiation process. Here, we studied the events occurring during the first 120 h after human MSC
transplantation into a large animal model. We demonstrate that MSC, shortly after engrafting different tissues, undergo
proliferation and rapidly initiate the differentiative process, changing their phenotype into tissue-specific cells. Thus, the final
level of tissue-specific cell contribution is not determined solely by the initial level of engraftment of the MSC within that organ,
but rather by the proliferative capability of the ensuing tissue-specific cells into which the MSC rapidly differentiate.
Furthermore, we show that true differentiation, and not cell fusion or transfer of mitochondria or membrane-derived vesicles
between transplanted and resident cells, is the primary mechanism contributing to the change of phenotype of MSC upon
transplantation.
© 2008 Elsevier B.V. All rights reserved.Introduction
The knowledge that mammalian stem cells can differentiate
into cell types other than those of the original organ, and
even across different embryonic layers, opened the possibi-
lity of using these cells as a tool for the development of novel
therapeutic strategies. Not only human embryonic stem
cells, with their acknowledged broad differentiative poten-* Corresponding author. Fax: +1 775 784 1375.
E-mail address: galmeida@cabnr.unr.edu (G. Almeida-Porada).
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University Park, PA 16802, USA.
1873-5061/$ – see front matter © 2008 Elsevier B.V. All rights reserved
doi:10.1016/j.scr.2008.08.002tial (Lerou and Daley, 2005), but also adult cells such as
multipotent adult progenitor cells (Jiang et al., 2002) or the
very small embryonic-like stem cells (Kucia et al., 2006a)
have all now been shown to contribute to and/or improve
repair in a broad range of tissues. Another cell that has
received a great deal of attention as being very promising for
cellular replacement therapies is the bone marrow-derived
mesenchymal stem cell (MSC) (also interchangeably referred
to as marrow stromal cells and stromal precursor cells), the
existence of which was first suggested in the pioneering
studies of Friedenstein (1990). The in vitro and in vivo
differentiation of MSC into the various mesenchymal cell
types found within the bone marrow has now been described
by numerous laboratories, and the conditions to bring about.
126 E.J. Colletti et al.each of these differentiative pathways have been delineated
in detail (Caplan, 1994; Pittenger et al., 1999). Recently,
MSC-like cells with differentiative potential similar to those
derived from the bone marrow have been isolated and
characterized in numerous tissues, such as cord blood
(Zvaifler et al., 2000), peripheral blood (O'Donoghue et al.,
2003; Ukai et al., 2007), placenta (Fukuchi et al., 2004), liver
(Airey et al., 2004), kidney (Almeida-Porada et al., 2002),
lung (In 't Anker et al., 2003), fat (Zuk et al., 2002), and even
amniotic fluid (In 't Anker et al., 2004). All of these cells have
in common the cellular and morphologic characteristics of
bone-marrow-derived MSC, as well as the ability to expand
considerably and differentiate into different tissue-specific
cell types and/or contribute to the functional improvement
of the engrafted organ(s) (Airey et al., 2004; Chamberlain et
al., 2007; Kogler et al., 2004; Liechty et al., 2000; Meyerrose
et al., 2007). However, since in many instances MSC appear
to play a role in the repair of the injured tissue without
evidence of engraftment or differentiation, the ability of
MSC to contribute significantly to the organTs specific cell
types has been questioned. It is clear that the characteristics
of the tissue itself and the kind of deficiency or injury, if
injury is the stimulus for cell differentiation, are important
variables in determining whether true MSC differentiation
can be observed after engraftment (Camargo et al., 2004;
Scott, 2004; Theise and Krause, 2002; Wagers and Weissman,
2004; Wang et al., 2003a). While it is probable that MSC
contribute to organ repair through a variety of mechanisms,
including suppression of inflammatory and immune responses
and/or secretion of factors stimulating the regeneration of
endogenous cells, other mechanisms such as cell fusion and
transfer of mitochondrial or membrane derived-vesicles
between cells (Aliotta et al., 2007; Almeida-Porada et al.,
2004; Alvarez-Dolado et al., 2003; Camargo et al., 2004;
Kucia et al., 2005, 2006b; Ratajczak et al., 2006; Scott,
2004; Spees et al., 2006; Theise and Krause, 2002;
Vassilopoulos et al., 2003; Verfaillie, 2005; Wagers and
Weissman, 2004; Wang et al., 2003b; Weimann et al., 2003)
have also been put forward as possible explanations for the
seemingly broad differentiative capacity of MSC.
In this study, we followed the early events that occur after
MSC transplantation, and we demonstrated in the fetal sheep
transplantation model that human MSC proliferate and
promptly commence the differentiative process into tissue-
specific cell types. Furthermore, we determined that cell
fusion and/or transfer of mitochondria or membrane-derived
vesicles between transplanted and resident cells is not the
primary mechanism contributing to the change of phenotype
of MSC upon transplantation. By demonstrating that MSC do
in fact harbor the intrinsic ability to differentiate into tissue-
specific cell types in multiple organs following transplanta-
tion, we hope that the stage will now be set for beginning to
delineate the means of increasing the efficiency of both
delivery and selective differentiation of MSC into desired
target cell types for their use in stem-cell-based regenera-
tive therapies.Results
Several studies have been performed to examine the
differentiative potential and the dynamic in vivo distributionof human MSC after transplantation. However, thus far, these
studies have either focused on merely establishing homing
patterns of MSC to various organs soon after transplant
(Schrepfer et al., 2007) or evaluated the differentiative
potential of MSC only at several weeks or months after the
transplant, making it likely that numerous events, such as
proliferation, multistep differentiation, or even cell death
could already have taken place prior to analysis (Chamber-
lain et al., 2007; Liechty et al., 2000; Meyerrose et al., 2007;
Phinney and Prockop, 2007). In the present study, we sought
to define the therapeutic potential of MSC better by
elucidating the mechanistic pathways through which MSC
appear capable of giving rise to functional differentiated
tissue-specific cells and thus contribute to organ regenera-
tion. To answer this fundamental question, we focused on
defining the fate of MSC at very early time points after
transplantation, when MSC first begin colonizing their target
tissues.
Human MSC isolated based on Stro-1+, CD45−, Gly-A−
(Airey et al., 2004) were labeled prior to transplantation with
either carboxyfluorescein (diacetate) succinimidyl ester
(CFSE), which irreversibly couples to both intracellular and
cell-surface proteins (Quah et al., 2007; Slavik et al., 2004),
or 1,1V-dioctadecyl-3,3,3V,3V-tetramethylindocarbocyanine
perchlorate (DiD), which efficiently labels all cell mem-
branes, membrane-derived vesicles, and intracellular orga-
nelles such as mitochondria (Anderson and Trgovcich-Zacok,
1995; Onfelt et al., 2006; Zorov et al., 2004). Efficiency of
labeling and viability of cells were assessed prior to cell
transplantation. Ninety-nine to one hundred percent of the
MSC were efficiently labeled with CFSE or DiD, while cell
viability remained 98–100k (Supplementary Figs. 1A–C).
Fetal sheep (n=36) at 55–60 days of gestation were
then transplanted by intraperitoneal injection with either
2106 CFSE-positive MSC alone (n=11) or 1106 CFSE-
positive MSC in combination with 1106 DiD-positive MSC
(n=25) corresponding to a dose of 2107 cells/kg fetal
weight. This transplantation procedure has been used by
us and others successfully, resulting in minimal fetal
losses posttransplantation (Chamberlain et al., 2007;
Liechty et al., 2000). Flow-cytometric analysis of periph-
eral blood and peritoneal lavage showed that transplanted
cells migrate into the systemic circulation as early as 20 h
posttransplant and were absent from the peritoneal cavity
by 96 h after injection. Thus, evaluation of the liver, lung,
and brain for the presence of donor CFSE+ or DiD+ MSC by
confocal microscopy, as described under Materials and
Methods, commenced at 20 h posttransplant and continued
at 25, 30, 40, 60, and 120 h after transplantation in all of
the studies.Small percentages of primary MSC engraftment
translate into substantive absolute numbers of
tissue-resident MSC
Analysis of liver, lung, and brain at 20 h postinjection
demonstrated that the transplanted MSC, despite being
detected in the circulation, had not reached any of these
organs. The percentage of engraftment and total number of
human MSC detected in each organ at different times
posttransplantation are shown in Table 1. Transplanted MSC
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127Generation of tissue-specific cells from MSCwere first detected in the liver parenchyma at 25 h
posttransplantation at levels of 0.033F0.007k. To deter-
mine the absolute number of cells migrating to each of the
tissues, we normalized the number of engrafted cells per
tissue mass. Thus, after accounting for the average number
of cells comprising a fetal sheep liver at this gestational age,
it was calculated that a total of 1.16105 MSC had reached
this organ at this first time point. At 30 h postinjection the
number of MSC found in the recipientTs liver doubled, with
0.062F0.006k, or 2.15105, of the cells within this organ
being of donor origin. This number continued to increase in
the next hours, to reach the maximal level of engraftment of
0.13F0.02k at 40 h posttransplant and a total number of
donor-derived cells of 4.64105. MSC reached the lung only
at 30 h posttransplantation, constituting 0.028F0.007k, or
13.4105, of the total cells in this organ. The number of
human MSC continued to increase at 40 and 60 h, reaching
0.097F0.014k or 45105 at 120 h. Settlement of MSC in the
brain started at 40 h, a later time point than the liver and
lung, with a level of engraftment of 0.034F0.008k, or
1.7105 total cells. This number rose to its maximum of
0.079F0.006k or 3.28105 total cells at 60 h.
To investigate the relative biodistribution of the in-
jected MSC, we determined, at the time when donor cells
were first detected, what percentage of the total trans-
planted MSC were present in the different organs. While
only 5.8k of the transplanted MSC homed to the liver and
8.6k to the brain, 67k of the transplanted MSC were found
in the lung.
These data show that, even at a dose of 2107cells/kg,
the levels of primary engraftment of human MSC in the liver,
lung, and brain are very low. The observed levels would often
be considered negligible, or even absent, depending on the
sensitivity of the method of detection utilized. However,
after taking into consideration the inherent tissue cellularity,
these seemingly low percentages of primary engraftment in
fact correspond to substantive absolute numbers of MSC
lodged in each organ.
Human MSC proliferate and differentiate into
tissue-specific cells in various organs
We next investigated what events took place within the
transplanted cells upon lodging within their target organs.
We began by evaluating whether the transplanted cells
underwent proliferation upon engraftment and determining
whether this proliferation took place before or after the
MSC had initiated differentiation into tissue-specific cell
types within the respective tissue. Tissue sections from the
engrafted organs, collected at 25, 30, 40, 60, and 120 h
after transplantation, were stained with Ki67, a marker of
cell division, and analyzed under confocal microscopy as
described under Materials and Methods. At all time points,
95k of the CFSE+ or DiD+ cells in each tissue also exhibited
Ki67 positivity. Since only 30k of the MSC in a parallel
culture exhibited Ki67 positivity at the time of culture
harvest prior to transplant (Supplementary Fig. 2), this
finding suggests that many of the engrafted cells either
began or continued to proliferate upon lodging within the
various organs. Figs. 1E–G (liver), Figs. 2H–K (lung), and
Figs. 3D–F (brain) show representative tissue sections with
DiD+ and CFSE+ cells undergoing division in close association
Figure 1 Human MSC initiate the differentiative process into liver cells (A–D) and proliferate (E, F) within the liver parenchyma. (A) A
cluster of MSC DiD+ and CFSE+ cells expressing a-fetoprotein can be seen in a representative section of liver tissue, harvested at 30 h
posttransplant and stained with antibody against a-fetoprotein (AlexaFluor 594, red). (B) Detail at 40 original magnification from (A)
showing the cluster of DiD+ (blue) and CFSE+ (green) MSC. (C) Expression of a-fetoprotein (red) by the liver cells. (D) Merge of (B) and (C)
showing DiD+ and CFSE+ cells expressing a-fetoprotein (magenta and yellow, respectively). (E) Representative liver section with DiD+ and
CFSE+ MSC. (F) Same field of view with liver section stained with anti-Ki67 antibody. (G) Merge of (E) and (F) showing DiD+ and CFSE+ cells
undergoing division in close associationwith proliferating endogenous sheepcells (Ki67 positive, CFSE/DiD negative). Scale bars: (A) 100 lm,
(B–G) 25 lm.
128 E.J. Colletti et al.with proliferating endogenous sheep cells (Ki67 positive,
CFSE/DiD negative). These studies demonstrate the ability
of MSC to proliferate within the host tissues, suggesting thatFigure 2 Human MSC differentiate into type II pneumocytes
Representative lung tissue section at 40 h posttransplant, stained w
cluster of MSC CFSE+ cells can be seen (green). (B) Detail at 40 orig
MSC. (C) Expression of prosurfactant-B (red) by cells in the lung pare
prosurfactant-B (double-positive cells appear yellow). (E) Detail
parenchyma at 40 h posttransplant. (F) Expression of caveolin-1 (red)
that DiD-positive MSC fail to express caveolin-1. (H) Representative l
section stained with anti-Ki67 antibody. (K) Merge of (H) and (J) sh
endogenous sheep cells (Ki67 positive, CFSE negative). Scale bars: (the higher levels of engraftment observed at later time
points were due, at least in part, to the proliferation of the
MSC that had engrafted earlier on and were not solely a(A–D) and proliferate (H–K) shortly after engraftment. (A)
ith an antibody against prosurfactant-B (AlexaFluor 594, red); a
inal magnification from (A) showing the cluster of CFSE+ (green)
nchyma. (D) Merge of (B) and (C) showing CFSE+ cells expressing
at 40 original magnification showing MSC DiD+ in the lung
by cells in the lung parenchyma. (G) Merge of (E) and (F) showing
ung tissue with CFSE+ MSC. (J) Same field of view with lung tissue
owing CFSE+ cell dividing in close association with proliferating
A) 100 lm, (B–K) 25 lm.
129Generation of tissue-specific cells from MSCresult of the continued lodging of transplanted cells within
the tissue.
To determine the timeline of MSC differentiation into
organ-specific cell types, we examined liver, brain, and lung
tissue sections by immunofluorescence using various cell-
specific markers that were not expressed by MSC prior to
transplant (Supplementary Figs. 1D–F). We then examinedthese tissues by confocal microscopy for evidence of cells
that were positive for CFSE or DiD and were simultaneously
expressing cell-specific markers for each of the engrafted
tissues. a-Fetoprotein was chosen as the marker of MSC
induction toward a hepatic phenotype, since during normal
liver development, the up-regulation of gene transcripts
encoding a-fetoprotein and albumin is thought to mark the
Figure 3 Human MSC up-regulate the expression of proteins related to neural differentiation (A–C) and proliferate (D–F) soon
after engraftment. (A) A cluster of DiD+ and CFSE+ MSC can be seen in a representative section of brain tissue, harvested at 40 h
posttransplant. (B) Same field of view as (A), stained with an antibody against Tau (AlexaFluor 594, red). (C) Merge of (A) and (B)
showing DiD+ and CFSE+ cells expressing Tau (magenta and yellow, respectively). (D) Representative brain tissue with CFSE+ and
DiD+ MSC. (E) Same field of view as (D), stained with anti-Ki67 antibody. (F) Merge of (D) and (E) showing DiD+ and CFSE+ cells
undergoing division in close association with proliferating endogenous sheep cells (Ki67 positive, CFSE/DiD negative). Scale bars:
(A) 100 lm, (B–G) 25 lm.
130 E.J. Colletti et al.first evidence of hepatic specification and emergence of the
hepatoblast (Gouon-Evans et al., 2006). But, because during
this period protein expression of albumin occurs later than
that of a-fetoprotein, we used expression of the latter as
evidence of initiation of differentiation of MSC into a liver-
like phenotype (Nava et al., 2005). At 25 h posttransplant,
the first time point at which MSC were detected in the liver,
CFSE+ or DiD+ cells (1.16F0.0105) were already expres-
sing a-fetoprotein, demonstrating that MSC rapidly
switched to a fetal hepatocyte-like phenotype upon liver
engraftment. Fig. 1A shows a representative section of liver
tissue, harvested at 30 h posttransplant, stained with
antibody against a-fetoprotein. As can be seen, most of the
recipientTs hepatic cells are already expressing a-fetoprotein.
This figure also shows a cluster of CFSE- and DiD-positive cells
expressing a-fetoprotein (AFP), demonstrating their differen-
tiation toward a hepatoblast-like phenotype (total No. of MSC
expressing a-fetoprotein: 2.1F0.0105). To evaluate MSC
differentiation in the lung, we examined the expression of
surfactant protein B, since this protein is expressed in type II
pneumocytes early in gestation (Khoor et al., 1994). We also
looked at caveolin-1 expression since it is a marker of matu-
ration and differentiation of lung alveolar epithelial type II
cells into a type I phenotype (Barar et al., 2007). CFSE- andDiD-
positive cells were found to express surfactant protein B
(13.4F0.0105) as soon as they first engrafted in the lung at
30 h posttransplantation, and they continued to express this
protein throughout the evaluation period. By contrast, up to
120 h posttransplant, the last time point of our analysis,
caveolin-1 was still not being expressed by the transplanted
MSC. This demonstrates that the transplanted MSC assumed aphenotype that is consistent with differentiation to a type II
epithelial cell, but not to a more mature type I. Figs. 2A–D
show representative lung tissue sections at 40 h posttrans-
plant, stained with an antibody against prosurfactant-B. This
figure shows that a cluster of CFSE-labeled MSC is expressing
prosurfactant-B, while Figs. 2E–G show that DiD-positive MSC
failed to express caveolin-1 throughout our study (total No. of
MSC expressing prosurfactant-B: 31F0.3105).
To investigate the differentiation of MSC into cells with a
neural phenotype upon engraftment into the brain tissue, we
examined whether CFSE- and DiD-positive cells were also
expressing Tau and/or synaptophysin. Tau is widely expressed
in the fetal brain during development and correlates with
neurite growth and axonal development in neurons and neural
cell lines upon in vitro culture (Kempf et al., 1996), while
synaptophysin is a presynaptic vesicle glycoprotein that is a
reliable marker of nerve terminal differentiation (Sarnat and
Born, 1999). All of the transplantedDiD- and CFSE-positiveMSC
expressed Tau promptly at the first time point of 40 h
posttransplantation (1.7F0.0105), the first point at which
these cells were found in the brain. Figs. 3A–C show DiD- and
CFSE-positive MSC expressing Tau at 40 h posttransplant,
demonstrating thatMSCquickly up-regulated the expression of
proteins related to neural differentiation. By contrast, at the
same time point of 40 h posttransplant, synaptophysin was
found to be expressed in approximately 56k of the trans-
planted MSC (9.6F0.0104). Figs. 4B–D show a DiD-positive
cell that was negative for synaptophysin, while Figs. 4E–G
show a CFSE-positive cell that is expressing synaptophysin.
Nevertheless, at 60 h posttransplant, all of the MSC visualized
in the brain were expressing synaptophysin (4F0.0105).
Figure 4 Human MSC engrafted in brain start expressing synaptophysin at later time points posttransplant. (A) DiD+ and CFSE+ MSC
can be seen in a representative section of brain tissue, harvested at 40 h posttransplant and stained with antibody against
synaptophysin (AlexaFluor 594, red). (B) Detail at 40 original magnification from (A) showing DiD+ MSC (blue). (C) Expression of
synaptophysin (red) by the brain cells. (D) Merge of (B) and (C) showing that these DiD+ cells are not yet expressing synaptophysin. (E)
Detail at 40 original magnification from (A) showing CFSE+ MSC (green). (F) Expression of synaptophysin (red) by the brain cells. (G)
Merge of (E) and (F) showing CFSE+ MSC expressing synaptophysin. Scale bars: (A) 100 lm, (B–G) 25 lm.
131Generation of tissue-specific cells from MSCOverall, these results show that transplanted MSC, after
reaching brain, liver, or lung, rapidly undergo proliferation and
differentiation, leading to a change in MSC phenotype toward
tissue-specific cell types. To confirm further that expression of
these markers by the engrafted MSC was indeed due to
differentiation into tissue-specific cells, additional experi-
ments were performed in which antibodies presumed to be
tissue-specific were used to stain sections from unrelated
tissues exhibiting human cell engraftment. Supplementary
Figs. 3–5 show the results of these swapped antibody
experiments in different tissues and clearly demonstrate
that while engrafted MSC in each of these tissues expressmarkers specific to the tissue in question, they do not express
markers normally present in other tissues. For example, MSC
engrafted within the liver express AFP, but they do not express
Tau. Likewise, MSC that have engrafted the lung express
prosurfactant-B, but do not express AFP, while MSC that
engraft within the brain express Tau, but do not express
prosurfactant-B. These studies thus demonstrate the specifi-
city of the antibodies we employed and confirm that the
transplanted MSC were not expressing multiple btissue-
specificQ antigens as a result of transplantation into a fetal
environment, but rather, began to express each of these
markers only upon engraftment within the respective tissue.
132 E.J. Colletti et al.Human mesenchymal stem cells differentiate into
tissue-specific cells in the absence of fusion or
membrane/mitochondrial transfer
In an effort to delineate the mechanisms responsible for the
observed generation of tissue-specific cells by MSC, we next
investigated whether the rapid expression of tissue-specificFigure 5 Human MSC differentiate into liver cells in the absence
(G–M). (A) A cluster of CFSE+ (green) MSC in a representative sectio
FISH with a sheep-specific probe (red), nuclei counterstained wit
showing only the green (CFSE) and red (sheep-specific FISH probe) c
(sheep-specific FISH probe) and blue (DAPI nuclear counterstain) ch
analyzed by FISH using a human-specific probe (red), with nuclei cou
section, showing only the green (CFSE) and red (human-specific FISH
the red (human-specific FISH probe) and blue (DAPI nuclear counte
tissue section stained by FISH with a sheep-specific probe (red), nu
same tissue section, showing only the blue (DiD) and red (sheep-sp
showing only the red (sheep-specific FISH probe) and green (DAPI nuc
representative liver tissue section stained by FISH with a huma
pseudocolored green. (L) The same tissue section, showing only th
The same liver tissue section, showing only the red (human-specif
These pictures collectively show that CFSE+ and DiD+ donor ce
demonstrating that no fusion had occurred between the transpla
exclusive hybridization of DiD+ cells to the human probe demonst
between the donor human MSC and the neighboring recipient sheecell markers was due to true differentiation of the
transplanted MSC into tissue-specific cells or instead
resulted from the transfer of membrane vesicles/mitochon-
dria or fusion of MSC with resident tissue-specific cells within
each organ. To this end, we used confocal microscopy to
visualize cells that were positive for CFSE, which irreversibly
couples to both intracellular and cell-surface proteins (Quahof fusion (A–F) or membrane vesicular or mitochondria transfer
n of liver tissue obtained at 60 h posttransplant and stained by
h DAPI are pseudocolored blue. (B) The same tissue section,
hannels. (C) The same liver tissue section, showing only the red
annels. (D) Serial section of the same MSC CFSE+ cluster (green)
nterstained with DAPI (pseudocolored blue). (E) The same tissue
probe) channels. (F) The same liver tissue section, showing only
rstain) channels. (G) DiD+ (blue) MSC in a representative liver
clei counterstained with DAPI are pseudocolored green. (H) The
ecific FISH probe) channels. (J) The same liver tissue section,
lear counterstain) channels. (K) A cluster of DiD+ (blue) MSC in a
n-specific probe (red), nuclei counterstained with DAPI are
e blue (DiD) and red (human-specific FISH probe) channels. (M)
ic FISH probe) and green (DAPI nuclear counterstain) channels.
lls in the liver hybridized exclusively to the human probe,
nted MSC and the endogenous sheep cells. Furthermore, the
rates that no membrane or mitochondrial transfer took place
p liver cells. Scale bars: 25 lm.
Figure 6 Human MSC differentiate into lung cells in the absence of fusion (A–F) or membrane vesicular or mitochondria transfer
(G–M). (A) A cluster of CFSE+ (green) MSC in a representative section of lung tissue obtained at 60 h posttransplant and stained by
FISH with a sheep-specific probe (red), nuclei counterstained with DAPI are pseudocolored blue. (B) The same tissue section,
showing only the green (CFSE) and red (sheep-specific FISH probe) channels. (C) The same tissue section, showing only the red
(sheep-specific FISH probe) and blue (DAPI nuclear counterstain) channels. (D) A cluster of CFSE+ (green) MSC in a representative
lung tissue section analyzed by FISH using a human-specific probe (red), with nuclei counterstained with DAPI (pseudocolored blue).
(E) The same tissue section, showing only the green (CFSE) and red (human-specific FISH probe) channels. (F) The same lung tissue
section, showing only the red (human-specific FISH probe) and blue (DAPI nuclear counterstain) channels. (G) A cluster of DiD+
(blue) MSC in a representative lung tissue section stained by FISH with a sheep-specific probe (red), nuclei counterstained with DAPI
are pseudocolored green. (H) The same tissue section, showing only the blue (DiD) and red (sheep-specific FISH probe) channels. (J)
The same lung tissue section, showing only the red (sheep-specific FISH probe) and green (DAPI nuclear counterstain) channels. (K) A
cluster of DiD+ (blue) MSC in a representative lung tissue section stained by FISH with a human-specific probe (red), nuclei
counterstained with DAPI are pseudocolored green. (L) The same tissue section, showing only the blue (DiD) and red (human-specific
FISH probe) channels. (M) The same lung tissue section, showing only the red (human-specific FISH probe) and green (DAPI nuclear
counterstain) channels. Similar to the results obtained for liver, these pictures collectively show that CFSE+ and DiD+ donor cells in
the lung hybridized exclusively to the human probe, demonstrating that no fusion or membrane/mitochondrial transfer had
occurred between the transplanted MSC and the endogenous sheep cells. Scale bars: 25 lm.
133Generation of tissue-specific cells from MSCet al., 2007; Slavik et al., 2004), or DiD, which efficiently
labels all cell membranes and intracellular organelles, such
as mitochondria (Anderson and Trgovcich-Zacok, 1995;
Onfelt et al., 2006; Zorov et al., 2004), and performed
fluorescence in situ hybridization (FISH) using either a
human- or a sheep-specific probe. By examining the species
origin of the genomic DNA present within the nuclei of the
DiD+ or CFSE+ cells in each engrafted organ, we were able to
determine whether the transplanted MSC had undergonefusion or membrane/mitochondrial transfer. Figs. 5, 6, and 7
show tissue sections from liver, lung, and brain, respectively.
Columns A–C in each of these figures illustrate the result of
FISH using a sheep-specific probe, and columns D–F show
tissue sections analyzed by FISH using a human-specific
probe. CFSE+ cells in the liver, lung, and brain all hybridized
exclusively to the human probe, demonstrating that no
fusion had occurred between the transplanted MSC and the
endogenous sheep cells within the examined organs. Since
Figure 7 Human MSC differentiate into neural cells in the absence of fusion (A–F) or membrane vesicular or mitochondria transfer
(G–M). (A) A cluster of CFSE+ (green) MSC in a representative section of brain tissue obtained at 60 h posttransplant and stained by FISH
with a sheep-specific probe (red), nuclei counterstained with DAPI are pseudocolored blue. (B) The same tissue section, showing only
the green (CFSE) and red (sheep-specific FISH probe) channels. (C) The same tissue section, showing only the red (sheep-specific FISH
probe) and blue (DAPI nuclear counterstain) channels. (D) A cluster of CFSE+ (green) MSC in a representative brain tissue section
analyzed by FISH using a human-specific probe (red), with nuclei counterstained with DAPI (pseudocolored blue). (E) The same tissue
section, showing only the green (CFSE) and red (human-specific FISH probe) channels. (F) The same brain tissue section, showing only
the red (human-specific FISH probe) and blue (DAPI nuclear counterstain) channels. (G) A cluster of DiD+ (blue) MSC in a representative
brain tissue section stained by FISH with a sheep-specific probe (red), nuclei counterstained with DAPI are pseudocolored green. (H)
The same tissue section, showing only the blue (DiD) and red (sheep-specific FISH probe) channels. (J) The same brain tissue section,
showing only the red (sheep-specific FISH probe) and green (DAPI nuclear counterstain) channels. (K) A cluster of DiD+ (blue) MSC in a
representative brain tissue section stained by FISH with a human-specific probe (red), nuclei counterstained with DAPI are
pseudocolored green. (L) The same tissue section, showing only the blue (DiD) and red (human-specific FISH probe) channels. (M) The
same brain tissue section, showing only the red (human-specific FISH probe) and green (DAPI nuclear counterstain) channels. Similar to
the results obtained for liver and lung, these pictures collectively show that CFSE+ and DiD+ donor cells in the brain hybridized
exclusively to the human probe, demonstrating that no fusion or membrane/mitochondrial transfer had occurred between the
transplanted MSC and the endogenous sheep cells. Scale bars: 25 lm.
134 E.J. Colletti et al.the majority of studies thus far have focused on the role of
mitochondrial transfer from donor cells to recipient tissues
as a means of providing respiratory rescue to damaged or
injured host tissues/cells, and have suggested that this may
in fact be the mechanism whereby transplanted MSC provide
therapeutic benefit without the need for actual engraftment
(Spees et al., 2006), we also examined whether membrane
vesicles/mitochondria were transferred from the trans-planted human cells to the host sheep tissues. As can be
seen in columns G–J in Figs. 5, 6, and 7, all of the DiD-
positive cells were negative for sheep genomic DNA, while
columns K–M prove that every DiD-positive cell hybridized
exclusively to the human probe. This combinatorial approach
thus demonstrated that in the absence of disease or injury,
MSC gave rise to tissue-specific cell types in the absence of
cellular fusion or donor-to-recipient transfer of mitochondria
135Generation of tissue-specific cells from MSCor membrane vesicles. Nevertheless, despite the sensitivity
of these methods, the possibility exists that minute levels of
vesicle/organelle transfer could have occurred and fallen
below our limits of detection.Discussion
In the present studies we show that, upon transplantation
into a noninjury fetal model, human MSC engrafted in all of
the examined organs, began or continued proliferating, and
started differentiation into multiple tissue-specific cell
types. Nevertheless, even when we transplanted 20 million
cells/kg, the percentages of engrafted donor cells in the
different organs were low. It is important to note, however,
that the final level of tissue-specific cells generated by the
transplanted MSC within a given organ may not be deter-
mined solely by the initial level of engraftment and
proliferation of the MSC within that organ, but rather on
the ensuing proliferative capability of the tissue-specific
cells into which the MSC rapidly differentiate upon
engraftment. For example, in the case of the liver, the
MSC rapidly differentiate to form hepatoblasts, which, like
the MSC themselves, possess a high intrinsic proliferative
capacity (Mahieu-Caputo et al., 2004). For this reason, even
relatively low initial levels of donor MSC engraftment within
this organ can result in high long-term levels of donor-
derived hepatocytes through subsequent proliferation of
MSC-derived hepatoblast progeny (Chamberlain et al.,
2007). In contrast, in an organ such as the brain, the
rapid conversion of the engrafted MSC into a phenotype
consistent with terminally differentiated neurons would
probably preclude any further proliferation/expansion of
the donor cells, limiting the ultimate levels of engraftment
achieved in this tissue. This suggests that to achieve
clinically relevant levels of MSC engraftment able to
provide for suitable therapy, it will probably be necessary
to find ways to substantially increase the efficiency with
which the infused cells can be delivered to the specific
desired organ. For instance, the work by Sackstein et al.,
showing that converting the native CD44 glycoform found
on MSC into an E-selectin/L-selectin ligand resulted in
enhanced tropism of MSC to the bone (Sackstein et al.,
2008), elegantly illustrates how it may be possible in the
near future to unlock new pathways for increasing the
trafficking and homing of these cells to other organs.
These studies also suggest that transplanted MSC go
through a gradual program of differentiation, with the
subsequent cells sequentially expressing markers indicative
of progressive cell maturation. Because the differentiation
process of MSC into tissue-specific cells occurs promptly
upon engraftment, a deeper understanding of how the
differentiative process by which MSC give rise to tissue-
specific cells comes about is needed, so that novel
strategies can be developed to drive the proliferation of
the engrafted cells at specific steps of the differentiation
process, to achieve therapeutic levels of a particular cell
needed for correction of the disease in question.
Furthermore, we have also demonstrated that the
formation of tissue-specific cells from transplanted adult
human MSC occurs in several organs in the absence of
either fusion or donor-to-recipient mitochondrial/mem-brane transfer. Despite the sensitivity of the methods we
employed in the present study to address this issue, the
possibility still exists that minute levels of vesicle/
organelle transfer could have occurred and fallen below
our limits of detection. Nevertheless, it is likely that in the
fetal sheep model system, in the absence of injury or
disease, there are sufficient developmental cues present
within the physiologic inductive microenvironment to
induce up-regulation of tissue-specific genes within the
transplanted MSC that then lead to differentiation into cells
of the specific desired organ. This would be in agreement
with recent studies in which investigators showed that by
forcing adult cells to overexpress a small number of genes
normally associated with embryonic stem (ES) cells, they
were able to induce these adult cells to achieve totipo-
tency, thus providing strong evidence that adult stem cells,
under very specific conditions, possess the ability to change
the developmental clock and, in this case, to become an
ES-like cell (Takahashi et al., 2007; Wernig et al., 2007; Yu
et al., 2007). It is envisioned that further studies elucidat-
ing precisely which genes are required for adult stem cells
to differentiate into each of the tissue-specific cell types
will ultimately lead to the discovery of the means of
specifically up-regulating only the genes required to
produce the cell type needed for benefit in the disease
state in question. In our present studies, we have taken
advantage of the unique proliferative/inductive nature of
the fetal microenvironment to show that transplanted adult
MSC have the inherent ability to generate tissue-specific
cells rapidly in several tissues. It is important to note,
however, that while this model is well suited to defining the
mechanisms involved in this process, translation to clinical
application will require experiments in adult animals
exhibiting a specific defect/disease, to assess the impact
the diseased/proapoptotic microenvironment may have on
stem cell engraftment and differentiation. Thus, once the
requisite gene pathways have been elucidated and the means
of circumventing the hurdles that are present in injured/
diseased adult tissues have been developed, the stage will be
set for beginning to delineate the means of increasing the
efficiency of both delivery and selective differentiation of
MSC into desired target cell types, to be able finally to fully
exploit the potential of human MSC for their use in stem cell-
based regenerative therapies.Materials and methods
MSC isolation and characterization
Human fetal liver (18 to 22 weeks gestational age) was
purchased from Advanced Bioscience Resources (Alameda,
CA, USA). Fetal tissues were homogenized to yield single-
cell suspensions and enriched for Stro-1+ cells (Simmons
et al., 1994) (Stro-1 antibody was a kind gift from Dr. Paul
Simmons) by magnetic cell sorting (Miltenyi Biotec, Auburn,
CA, USA). Stro-1+ cells were plated at low density in MSC
growth medium (MSCGM) (Lonza, Allendale, NJ, USA). After
enrichment, MSC were expanded in MSCGM and cultured at
1104 to 5105 cells/cm2. Similar to bone-marrow-derived
MSC (Chamberlain et al., 2007), liver-derived MSC expressed
high levels of CD90, CD13, CD29, and CD105 and were
136 E.J. Colletti et al.negative for CD14, CD33, CD34, CD45, glycophorin A, and
HLA-DR. Liver-derived MSC were also evaluated for their
ability to fulfill the criteria of MSC by confirming their
ability to undergo differentiation along osteogenic and
adipogenic pathway in vitro, as previously described
(Chamberlain et al., 2007).
MSC labeling with CFSE and DiD
Cultures of MSC were suspended in HBSS containing 0.1k
bovine serum albumin (BSA) at a concentration of 2106
cells/ml in 2 ml of medium. A stock solution of 3 mM CFSE
(Sigma–Aldrich, St. Louis, MO, USA) in DMSO was diluted to
6 lM in PBS containing 0.1k BSA. One milliliter of CFSE
solution was mixed with 1 ml of MSC cell suspension to give
a final concentration of 3 lM and was allowed to incubate
for 10 min at 37 -C. MSCGM containing 13k fetal bovine
serum was used to quench the CFSE protein binding
reaction. The free CFSE was then removed by washing and
cells were suspended in injection medium, Hepes-buffered
salt solution with 0.1k BSA.
For DiD labeling, adherent MSC were cultured in tissue
culture flasks to a concentration of 5105 cells/cm2 in
MSCGM. To label cells, 25 ll of a stock solution of 1 mM DiD
oil (DiIC18(5) oil; Molecular Probes, Carlsbad, CA, USA) in
DMSO was added to 2 ml of serum-free medium to give a
final concentration of 12.5 lM. The growth medium was
removed from the flasks, then the MSC cultures were
incubated in the DiD labeling solution for 20 min at 37 -C.
The labeling solution was removed; the cells were rinsed
with medium and then allowed to incubate for 10 min in
warmed growth medium. The MSC were detached using
trypsin/EDTA (Lonza). Cells were then suspended in injec-
tion medium as described above. Efficiency of labeling and
viability of cells were assessed prior to cell transplantation
(Supplementary Fig. 1).
In utero transplantation of sheep fetuses
Thirty-six fetal sheep (bred and housed at the University of
Nevada Agricultural Experimental Station) at 55–60 days of
gestation (term: 145 days) were injected intraperitoneally
with MSC labeled with CFSE alone (n=11) or in combination
with DiD (n=25) at a dose of 2107cells/kg (estimated fetal
body wt) in 0.5–1.0 ml as previously described (Airey et al.,
2004; Chamberlain et al., 2007; Liechty et al., 2000).
Animals were euthanized and tissues were harvested starting
at 20 h posttransplant and continued at 25, 30, 40, 60, and
120 h (Table 1). All procedures were in accordance with
University of Nevada IACUC guidelines.
Tissue preparation
Tissues were dissected and washed with ice-cold PBS, cut
into 5-mm cubes, and immersed in ice-cold PBS containing
4k paraformaldehyde for 1 h. After cryoprotection in PBS
containing increasing sucrose concentrations, from 5, 10, 15,
to 20k, tissues were incubated in 2 parts 20k sucrose, 1 part
OCT compound (TissueTec, Torrance, CA, USA) for 1 h and
then embedded in fresh solution by rapid freezing in
isopentane-cooled in liquid nitrogen. A Leica Minotome was
used to section each tissue, and cryosections 7 to 10 lm thickwere adhered to variously coated slides (Fisher Superfrost,
Surgipath Xtra, or Vectabond treated) according to tissue
adherence preferences.
Immunohistochemical analysis
Tissue sections were washed with PBS and blocked in PBS
containing 10k normal serum from the species of origin of
the secondary antibody or 2k BSA. Sections were then
incubated in PBS with 2k normal goat serum and primary
antibody overnight at 4 -C. Primary antibodies were against
the following proteins: Tau (BioGenex), Ki67 (Neomakers),
prosurfactant-B (Chemicon), caveolin-1 (BD Transduction
Laboratories), a-fetoprotein (Abcam), and synaptophysin
(Biogenex). Slides were washed with PBS with 2k BSA and
then incubated with secondary antibody in PBS with 2k BSA
for 1 h at 4 -C. Secondary antibodies were conjugated to
Alexa 488, 568, 594, or 633.
Data analysis and statistics
At least five different tissue sections were analyzed from
each of the organs of the transplanted animals at each time
point. An average of at least 50,000 total cells were counted
per tissue section and the numbers of human CFSE- and/or
DiD-positive cells in each section determined as a percen-
tage of the total number of cells. The mean percentages of
engraftment were then calculated by averaging the results
obtained from all five sections from the animals at each
time point of analysis, and standard deviation was deter-
mined for each time point to obtain the presented results.
To determine the percentage of the total transplanted MSC
that migrated to a specific tissue we used the following
formula:
k human cells=tissueð Þ  total No: cells=organð Þ½ 
=total No: injected cells:
Fluorescence in situ hybridization
FISH analysis of tissue sections was performed as previously
described (Chamberlain et al., 2007). Briefly, human- and
sheep-specific probes, generated as described in the
Supplementary Materials and Methods, were denatured at
95 -C for 5 min and then allowed to renature at 37 -C for 3 h.
Frozen sections 10 lm thick were washed in 2 SSC at 37 -C
for 30 min and then dehydrated in ethanol. Sections for
sheep FISH analysis were treated with 12.5 lg/ml proteinase
K for 10 min at 37 -C, while sections for human FISH analysis
were treated with 10 lg/ml proteinase K and incubated
at room temperature. Sections were washed with water for
5 min and then 2 SSC for 5 min and dehydrated in ice-cold
ethanol. Sections were denatured at 85 -C for 3 min in
preheated 70k formamide in 2 SSC, pH 7.0, and then
dehydrated with ice-cold ethanol. Probe was applied to
sections at 45 -C, sealed with a coverslip, and incubated
overnight at 42 -C. Coverslips were removed by immersing
slides in 2 SSC at 45 -C. Sections hybridized with sheep-
specific probe were washed twice with preheated 50k
formamide in 2 SSC, pH 7.0, for 5 min and then washed
with 0.1 SSC twice, 5min each, at 45 -C. Sections hybridized
137Generation of tissue-specific cells from MSCwith human-specific probe were washed once with 2 SSC,
pH 7.0, at 45--C for 5 min and then washed twice with room-
temperature PBS with 0.1k Triton X. Finally, sections were
washed with PBS, treated with DAPI (Biogenex), and sealed
with Cytoseal 60 for use with confocal microscopy.
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